Related Experiment Videos
[Controlled double-blind study (SAMe-imipramine) in depressive syndromes]
Minerva Medica
|November 17, 1975
Insights
S-Adenosylmethionine and Imipramine showed similar efficacy in a three-week clinical trial. While Hamilton Rating scores revealed no significant differences, slight improvements favored S-Adenosylmethionine in treating patients.
Area of Science:
- Psychiatry and Pharmacology
- Clinical Neuroscience
Background:
- Depression is a significant global health concern.
- Pharmacological interventions are crucial for managing depressive symptoms.
- S-Adenosylmethionine (SAMe) and Imipramine are established treatments.
Purpose of the Study:
- To compare the efficacy of S-Adenosylmethionine and Imipramine.
- To evaluate treatment outcomes in a double-blind clinical trial.
Main Methods:
- A double-blind clinical trial involving 31 patients.
- Treatment with S-Adenosylmethionine (25 mg i.m. thrice daily) or Imipramine (25 mg i.m. thrice daily).
- Administration for a duration of three weeks.
Main Results:
- No statistically significant differences in Hamilton Rating scores between the two treatment groups.
- A trend favoring S-Adenosylmethionine was observed in the slight differences noted.
- Both treatments were administered over a three-week period.
Conclusions:
- S-Adenosylmethionine and Imipramine demonstrate comparable efficacy in this short-term trial.
- S-Adenosylmethionine may offer a potential alternative treatment for depression.
- Further research is warranted to explore long-term effects and broader applications.
Abstract:
Thirty one patients were treated with either S-Adenosylmethionine or Imipramine in a double-blind clinical trial comparing S-Adenosylmethionine (25 mg i.m. three times daily) with Imipramine (25 mg i.m. three times daily) administered for a period of three weeks. Hamilton Rating scores showed no significant differences between treatments, but such slight differences as were observed favoured S-Adenosylmethionine.